Answers are grounded in this paper and cite their sources.
Since its introduction in 1996, the Consolidated Standards of Reporting Trials (CONSORT) statement has been widely used to facilitate transparent reporting of randomised controlled trials (RCTs), including those in oncology.1 Due to the unique methodological and implementation challenges associated with artificial intelligence (AI)-based interventions, the CONSORT group subsequently released the CONSORT-AI extension in 2020.2 This extension introduced 14 AI-specific items to strengthen the clarity, reproducibility and reliability of trials involving AI tools.
No takes yet. Share an insight, caveat, or question.
Kwong et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: